La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Precigen Croissance future

Future contrôle des critères 5/6

Precigen devrait augmenter ses bénéfices et ses revenus de 64.1% et de 58.2% par an respectivement, tandis que le BPA devrait croître de croître de 65.4% par an.

Informations clés

64.1%

Taux de croissance des bénéfices

65.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.2%
Taux de croissance des recettes	58.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	16 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:PGEN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	224	71	10	48	2
12/31/2025	22	-72	-72	-57	5
12/31/2024	4	-125	-95	-91	5
6/30/2024	4	-135	-78	-70	N/A
3/31/2024	5	-97	-68	-63	N/A
12/31/2023	6	-96	-68	-67	N/A
9/30/2023	7	-85	-67	-67	N/A
6/30/2023	22	-73	-75	-73	N/A
3/31/2023	23	-79	-68	-65	N/A
12/31/2022	27	-80	-70	-65	N/A
9/30/2022	29	-84	-72	-64	N/A
6/30/2022	15	-103	-66	-57	N/A
3/31/2022	16	-108	-66	-58	N/A
12/31/2021	14	-111	-63	-56	N/A
9/30/2021	30	-124	-64	-58	N/A
6/30/2021	50	-125	-64	-60	N/A
3/31/2021	77	-110	-71	-66	N/A
12/31/2020	32	-104	-85	-77	N/A
9/30/2020	101	-100	-103	-93	N/A
6/30/2020	96	-122	-118	-101	N/A
3/31/2020	98	-138	-150	-120	N/A
12/31/2019	91	-169	-174	-136	N/A
9/30/2019	108	-373	-186	-141	N/A
6/30/2019	122	-381	-188	-143	N/A
3/31/2019	134	-414	-180	-138	N/A
12/31/2018	151	-375	-166	-124	N/A
9/30/2018	194	-196	-165	-121	N/A
6/30/2018	208	-179	-164	-114	N/A
3/31/2018	217	-132	N/A	-109	N/A
12/31/2017	219	-71	N/A	-104	N/A
9/30/2017	200	-134	N/A	-94	N/A
6/30/2017	203	-123	N/A	-88	N/A
3/31/2017	201	-154	N/A	-77	N/A
12/31/2016	191	-187	N/A	-49	N/A
9/30/2016	186	-175	N/A	-19	N/A
6/30/2016	191	-184	N/A	49	N/A
3/31/2016	183	-176	N/A	45	N/A
12/31/2015	174	-84	N/A	36	N/A
9/30/2015	163	-33	N/A	14	N/A
6/30/2015	131	-47	N/A	-45	N/A
3/31/2015	98	-59	N/A	-42	N/A
12/31/2014	72	-82	N/A	-20	N/A
9/30/2014	48	-113	N/A	-21	N/A
6/30/2014	33	-52	N/A	-30	N/A
3/31/2014	28	-11	N/A	-30	N/A
12/31/2013	24	-57	N/A	-54	N/A
9/30/2013	23	-82	N/A	-56	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: PGEN devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.5% ).

Bénéfices vs marché: PGEN devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: PGEN devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PGEN ( 58.2% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PGEN ( 58.2% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de PGEN devrait être élevé dans 3 ans

Precigen Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates fall by 12%

Price target decreased by 41% to US$6.00

Price target increased by 11% to US$10.12

Price target increased by 11% to US$10.12

Consensus revenue estimates fall by 10%

Price target increased by 40% to US$9.12

Recent updates

Consensus revenue estimates fall by 12%

Price target decreased by 41% to US$6.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Shareholder dilution

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

New minor risk - Share price stability

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Price target increased by 11% to US$10.12

Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response

Price target increased by 11% to US$10.12

Precigen, Inc., Annual General Meeting, Jul 05, 2024

Consensus revenue estimates fall by 10%

Price target increased by 40% to US$9.12

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Price target decreased by 27% to US$6.50

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront